Subcutaneous C1-esterase inhibitor prophylaxis in hereditary angioedema (double-blind randomized placebo-controlled crossover Phase 3)

Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by CSL Limited. Primary endpoint: Time-normalized number of hereditary angioedema attacks. Started Sep 2013; status: completed.